DWP 14012

Drug Profile

DWP 14012

Alternative Names: DWP14012

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antiulcers; Gastric antisecretories
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastro-oesophageal reflux

Most Recent Events

  • 01 Aug 2017 Phase-II clinical trials in Gastro-oesophageal reflux in South Korea (PO) (NCT03184324)
  • 14 Jun 2017 Daewoong Pharmaceutical plans a phase II trial for Gastro oesophageal reflux (NCT03184324)
  • 01 Feb 2017 Daewoong Pharmaceutical completes a phase I trial in Peptic ulcer (In volunteers) in South Korea (PO) (NCT02757144)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top